COMP <GO>
ENOV vs AVR // ENTERPRISE SCALE & MARKET CAP
Enovis Corporation (NYSE) VS. Anteris Technologies Global Corp. (NASDAQ) • 15-METRIC TALLY: ENOV 8
— AVR 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: ENOV
LAST: $22.81 (+4.11%) • MKT CAP: $1.32B
market-cap
$1.32B
LAST: $6.42 (+5.25%) • MKT CAP: $625.9M
market-cap
$625.9M
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ENOV VS. AVR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ENOV | AVR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.80% | 70.30% | -10.50 | AVR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -32.70% | -35.00% | +2.30 | ENOV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.51% | -12.74% | +14.25 | ENOV | /fcf-yield <GO> |
| Operating Margin | -50.00% | -60.00% | +10.00 | ENOV | /operating-margins <GO> |
| Net Profit Margin | -52.70% | -60.00% | +7.30 | ENOV | /net-margins <GO> |
| Revenue Growth (YoY) | 6.70% | -29.20% | +35.90 | ENOV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 2/9 | +5.00 | ENOV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.3 | 44.1 | +17.20 | ENOV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.32B | $625.9M | $689.5M | ENOV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ENOV REV | AVR REV | ENOV GROSS % | AVR GROSS % | ENOV FCF | AVR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.25B | $1.9M | 59.8% | 70.3% | $19.9M | -$79.8M |
| FY 2024 | $2.11B | $2.7M | 56.0% | 46.8% | -$67.2M | -$63.5M |
| FY 2023 | $1.71B | — | — | — | $135.0M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ENOV // BETA —
AVR // BETA —